No results for ‘’
Kopran Ltd
NSE: KOPRAN BSE: 524280
â‚ą235.26
(0.24%)
Wed, 16 Sept 2026, 08:46 am
Market Cap (in Cr)1137.85
PE Ratio45.47
Dividend1.27
Health Technology
Pharmaceuticals: Major
24.5KKopran Analysis
dividend
- Unable to evaluate Kopran's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Kopran's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Kopran is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Kopran is profitable, therefore cash runway is not a concern.
- Kopran is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (39.4%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.4x debt.
- Kopran's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (87.7% vs 49% today).
- Interest payments on debt are well covered by earnings (EBIT is 5.2x coverage).
- Kopran's level of debt (49%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Kopran management team is over 5 years, this suggests they are a seasoned and experienced team.
- The average tenure for the Kopran board of directors is less than 3 years, this suggests a new board.
misc
- Kopran is not covered by any analysts.
- Kopran has significant price volatility in the past 3 months.
past
- Kopran has delivered over 20% year on year earnings growth in the past 5 years.
- Kopran used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Kopran's 1-year earnings growth is less than its 5-year average (11.3% vs 36.8%)
- Kopran's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Kopran has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Kopran's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (11.3% vs 22.7%).
value
- Kopran is good value based on assets compared to the IN Pharmaceuticals industry average.
- Kopran is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Kopran is good value based on earnings compared to the India market.
- 524280 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524280 is up 35.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524280 is up 35.5% outperforming the market in India which returned 8% over the past month.
- Kopran's share price is below the future cash flow value, but not at a moderate discount (< 20%).
- Kopran's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- 524280 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.